Compare F5 Inc (FFIV) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Revvity Inc — how do they compare? F5 Inc trades at $479.83 (market cap $26.14B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: F5 Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while F5 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Revvity Inc for 12 Days on average.
| FFIV | RVTY | |
|---|---|---|
Market Cap | $26.14B | $16.98B |
Volume | 503,146 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $479.83 | $157.36 |
52-Week Low | $223.99 | $82.26 |
Typical Hold Time | 38 Days | 12 Days |
Enterprise Value | $24.78B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $461.66, down 1.07% on the day, with a bullish technical outlook supported by moving averages and a strong fundamental backdrop. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $4.73 surpassing the $4.00 consensus, and maintains robust profitability with a net income margin of 21.95%. Recent news highlights leadership in WAAP platforms and AI security partnerships, reinforcing growth prospects.
The stock offers upside potential driven by earnings momentum and strategic positioning in application security, though valuation multiples like a P/E of 36.78 suggest premium pricing. Key risks include competitive pressures and market volatility, while analyst consensus leans neutral with a $416.60 price target below the current price, indicating cautious optimism tempered by valuation concerns.
RVTY trades at $152.16, down 0.94% today, near its recent 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a Zacks upgrade to Buy (2026-10-02) and the launch of a new Type 1 diabetes screening kit in Europe (Business Wire, 2026-09-24).
The outlook is positive, supported by earnings momentum and strategic expansions, but the stock's premium valuation (P/E of 73.15) and margin pressures pose risks. Analyst consensus is bullish with a $132.13 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
